Evidence map›Paper›PMID 25106414›Full record

ArticleJournal of medical genetics2014

The clinical significance of small copy number variants in neurodevelopmental disorders.

Reza Asadollahi, Beatrice Oneda, Pascal Joset, Silvia Azzarello-Burri, Deborah Bartholdi, Katharina Steindl, Marie Vincent, Joana Cobilanschi, Heinrich Sticht, Rosa Baldinger and 15 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of medical genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 1 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 1 synthesis or guideline pooled it, 103 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Further Delineation of the AUTS2 HX Repeat Domain-Related Phenotype.American journal of medical genetics. Part A · 2025
    Article
  7. Review
  8. Article
  9. Roles and regulation of δ-catenin in tumorigenesis and neuronal diseases.Frontiers in cell and developmental biology · 2025
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Loss ofFrontiers in neuroscience · 2023
    Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 6 institutions in 5 countries.

Reza AsadollahiInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich, Switzerland.
Beatrice OnedaInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich, Switzerland.
Pascal JosetInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich, Switzerland.
Silvia Azzarello-BurriInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich, Switzerland.
Deborah BartholdiInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich, Switzerland.
Katharina SteindlInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich, Switzerland.
Marie VincentInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich, Switzerland.
Joana CobilanschiInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich, Switzerland.
Heinrich StichtInstitute of Biochemistry, University of Erlangen-Nuremberg, Erlangen, Germany.
Rosa BaldingerInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich, Switzerland.
Regina ReissmannInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich, Switzerland.
Irene SudholtInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich, Switzerland.
Christian T ThielInstitute of Human Genetics, University of Erlangen-Nuremberg, Erlangen, Germany.
Arif B EkiciInstitute of Human Genetics, University of Erlangen-Nuremberg, Erlangen, Germany.
André ReisInstitute of Human Genetics, University of Erlangen-Nuremberg, Erlangen, Germany.
Emilia K BijlsmaDepartment of Clinical Genetics, Leiden University Medical Center (LUMC), Leiden, The Netherlands.
Joris AndrieuxInstitut de Génétique Médicale, Hôpital Jeanne de Flandre, CHRU de Lille, Lille, France.
Anne DieuxClinique de Génétique Guy Fontaine, Hôpital Jeanne de Flandre, CHRU de Lille, Lille, France.
David FitzPatrickMRC Human Genetics Unit, MRC Institute for Genetic and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
Susanne RitterChild Development Center, University Children's Hospital Zurich, Zurich, Switzerland.
Alessandra BaumerInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich, Switzerland.
Beatrice LatalChild Development Center, University Children's Hospital Zurich, Zurich, Switzerland.
Barbara PleckoDivision of Child Neurology, University Children's Hospital Zurich, Zurich, Switzerland.
Oskar G JenniChild Development Center, University Children's Hospital Zurich, Zurich, Switzerland.
Anita RauchInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich, Switzerland.
University of Zurich · CHFriedrich-Alexander-Universität Erlangen-Nürnberg · DEUniversity Children's Hospital Zurich · CHCentre Hospitalier Universitaire de Lille · FRLeiden University Medical Center · NLMRC Institute of Genetics and Molecular Medicine · GB

Funding

Medical Research Council MC_PC_U127561093
6 · The paper itself

Abstract

backgroundDespite abundant evidence for pathogenicity of large copy number variants (CNVs) in neurodevelopmental disorders (NDDs), the individual significance of genome-wide rare CNVs <500 kb has not been well elucidated in a clinical context.

methodsBy high-resolution chromosomal microarray analysis, we investigated the clinical significance of all rare non-polymorphic exonic CNVs sizing 1-500 kb in a cohort of 714 patients with undiagnosed NDDs.

resultsWe detected 96 rare CNVs <500 kb affecting coding regions, of which 58 (60.4%) were confirmed. 6 of 14 confirmed de novo, one of two homozygous and four heterozygous inherited CNVs affected the known microdeletion regions 17q21.31, 16p11.2 and 2p21 or OMIM morbid genes (CASK, CREBBP, PAFAH1B1, SATB2; AUTS2, NRXN3, GRM8). Two further de novo CNVs affecting single genes (MED13L, CTNND2) were instrumental in delineating novel recurrent conditions. For the first time, we here report exonic deletions of CTNND2 causing low normal IQ with learning difficulties with or without autism spectrum disorder. Additionally, we discovered a homozygous out-of-frame deletion of ACOT7 associated with features comparable to the published mouse model. In total, 24.1% of the confirmed small CNVs were categorised as pathogenic or likely pathogenic (median size 130 kb), 17.2% as likely benign, 3.4% represented incidental findings and 55.2% remained unclear.

conclusionsThese results verify the diagnostic relevance of genome-wide rare CNVs <500 kb, which were found pathogenic in ∼2% (14/714) of cases (1.1% de novo, 0.3% homozygous, 0.6% inherited) and highlight their inherent potential for discovery of new conditions.

Indexed as

ChildChild, PreschoolDevelopmental DisabilitiesDNA Copy Number VariationsFemaleHumansInfantMaleMiddle AgedSequence Analysis, DNAYoung AdultClinical GeneticsCopy-NumberDevelopmentalDiagnosticsGenome-Wide

Identifiers

PMID25106414
PMCPMC4173859
OpenAlexW2145034118

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.